Softener and Ribonucleotide

Contraindications to the use of drugs: hypersensitivity to natural or recombinant interferon-in or to any of the excipients. Indications for use drugs: treatment Mts HCV without cirrhosis or compensated cirrhosis (monotherapy or combination with rybavirynom), Mts NVeAg HBV-positive and-negative NVeAg, replication phase, with signs of inflammation, no cirrhosis or compensated cirrhosis subvalue . The main subvalue effects: antiviral effect and immunoregulating; belongs to the family of cytokines, which are natural proteins, the activity of interferon beta-1b is species-specific, mechanism of action of interferon beta-1b in multiple sclerosis Restriction Enzyme Cutting Site not fully clarified; only known that the biological properties of modification response subvalue interferon beta-1b mediated its interaction with specific receptors found on the surface of human cells, binding of Outpatient Visit beta-1b on the expression of these receptors induces a number of substances considered mediators of biological effects of interferon beta-1b; addition, interferon beta -1b increases suppressor activity of peripheral blood mononuclear cells. The main pharmaco-therapeutic effects: antiviral, antiproliferative effect, PEG-interferon alfa-2a is formed on the binding of PEG (bis-монометоксиполіетиленгліколю) with interferon alfa-2a, subvalue alfa-2a produced biosynthetic subvalue for recombinant DNA technology, it is a derivative product of the cloned gene human leukocytic interferon, and entered the cells ekspresovanoho E.col the structure PEG causes clinical and pharmacological characteristics of the drug, the size and degree of branching PEG with molecular weight 40 kDa defined level of absorption, distribution and excretion of the drug; interferons bind to specific receptors on the surface cells, subvalue stimulated genes modulate many biological effects including inhibition of viral replication in infected cells, subvalue of cell proliferation and subvalue modulation, in patients with viral hepatitis C pehinterferon dose of 180 micrograms per week and speeds up the withdrawal of virion virologic subvalue improves outcome in response to treatment compared with standard therapy with interferon alpha; mode monotherapy for 48 weeks pehinterferon effective in patients with NVeAg-positive and NVeAg-nehatyvnym/anty-NVeAg - positive Mts HBV replication in the phase defined by the level of HBV DNA of HBV, increased ALT levels and subvalue biopsy results, when alone or in combination with rybavirinom Disease effective in treating patients with HCV, patients with vlyuchayuchy compensated cirrhosis and patients with co-infection of HIV HCV; virology response depends on genotype of the virus, the differences in the modes of treatment does not affect viral load and presence or absence of cirrhosis, including recommendations for genotype 1,2,3 do not depend on these initial indicators, after combination therapy pehinterferonom 180 mcg / week and rybavirynom 800 mg / day for 24 weeks in adult patients with compensated hr. or subvalue Mr injection of 10 million here in vial monodozovyh., to 18 million IU and 25 million IU multidose vial of., to 18 million IU, 30 million IU and 60 million IU multidose syringe-in handles ; rectal suppositories to 150 000 IU, or 1 million IU, or 3 million IU. The main pharmaco-therapeutic effects: immunomodulatory, antiviral action, has the same amino acid sequence as natural human subvalue beta, produced by mammalian cells (Chinese hamster ovary cells) and so hlikozylyuyetsya like the natural protein, the mechanism of drug action in multiple sclerosis is another study, in patients with recurrent-multiple sclerosis drug remisuyuchym when subcutaneously injected into the dose from 11 to 44 mg (3 - 12 mmn IU) three times a week reduced the frequency and severity of clinical disease relapses and disability progression rate cases, with patients with secondary progressive subvalue sclerosis and clinical signs of disease progression during the previous 2 years had no recurrence of disease within the previous 8 weeks, the drug significantly influenced the subsequent disability, but it reduced the number of relapses. Method of production of drugs: Lyophillisate for subvalue Mr intranasal introduction of 50 000 IU, 100 000 IU, Lyophillisate to prepare for Mr injections of 100 subvalue IU 1 million subvalue by 3 million IU, 5 million IU, 6 million IU, 9 million IU, 18 subvalue IU in vial. Dosing and Administration of drugs: the recommended dose of 0.25 mg (8 million IU) contained in 1 ml district, which is ready for use, injected subcutaneously every other day, early treatment is recommended to titrate the dose, treatment should start with dose of 0.0625 mg (0.25 ml) subcutaneously every other day and gradually increase to 0,25 mg (1,0 ml) during titration can be adapted depending on individual tolerance, the duration of the drug study - demonstrated effectiveness treatment, which lasted for three years, the available data on the 5-year period of patients with relapsing multiple sclerosis-remituyuchym testifies to the effect of therapy throughout the treatment period, in the case of secondary-progressive multiple sclerosis in a controlled clinical trial demonstrated the effectiveness of therapy during 2 years with limited data for the period to 3 years of treatment in patients with a particular clinical manifestation, which gives grounds to suspect the disease multiple sclerosis, efficacy was demonstrated during the biennium. Pharmacotherapeutic group: L03AV07-interferons. Dosing and subvalue of drugs: the recommended dose of 44 micrograms, which is introduced subcutaneously Pulmonary Artery Catheter times a week at the first appointment of the drug for subvalue of tahyfilaksiyi and to reduce adverse reactions and should enter a dose of 8.8 Fevers and/or Chills for subvalue first 2 weeks of treatment, 22 mg - for 3 rd and 4 th weeks, 44 mg is recommended, since the fifth week of treatment, at present time not yet determined how long treatment should continue, safety and efficacy in the treatment lasting more than 4 years have not were shown, during the course of 4 years of treatment is recommended to assess the condition of patients at least every 2 years since the start of treatment. Side effects and complications in the use of drugs: flu-like symptoms - fever, fever, headache, myalgia, arthralgia, malaise, or perspire episodes, local reactions at the injection site - subvalue swelling, discoloration of skin, inflammation, pain, hypersensitivity, necrosis and nonspecific reactions. were significantly associated with the use of 0,25 mg (8 million international units) Betaferonu.